They have extensively examined the lung tumour microenvironment revealing diverse T-cell functions linked to patient prognosis, relevance of diversity of B cells in NSCLC for anti-tumour therapy, multiple states of tumour-infiltrating myeloid cells, proposing them as a new target in immunotherapy, as well as the association of tissue-resident neutrophils with anti-PDL1 therapy failure7,10–14. The gene discussed is CD274; the disease is non-small cell lung carcinoma.